Dexcom (DXCM) Stock Forecast & Price Target

Compare

4,392 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DXCM Analyst Ratings

Strong Buy

17 Buy

3 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$85.82

▲(17.43% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $85.82 with a high forecast of $112.00 and a low forecast of $68.00. The average price target represents a 17.43% change from the last price of $73.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","71":"$71","85":"$85","99":"$99","113":"$113"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,71,85,99,113],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.53,75.56615384615385,78.60230769230769,81.63846153846154,84.67461538461538,87.71076923076923,90.74692307692308,93.78307692307692,96.81923076923077,99.85538461538462,102.89153846153846,105.92769230769231,108.96384615384616,{"y":112,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.53,73.55230769230769,74.57461538461538,75.59692307692308,76.61923076923077,77.64153846153846,78.66384615384615,79.68615384615384,80.70846153846153,81.73076923076923,82.75307692307692,83.77538461538461,84.7976923076923,{"y":85.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.53,72.18153846153847,71.83307692307693,71.48461538461538,71.13615384615385,70.78769230769231,70.43923076923078,70.09076923076923,69.74230769230769,69.39384615384616,69.04538461538462,68.69692307692307,68.34846153846154,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":86.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$112.00

Average Price Target$85.82

Lowest Price Target$68.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Marie Thibault

BTIG

$85

Buy

16.31%

Upside

Reiterated

02/18/26

BTIG Reaffirms Their Buy Rating on Dexcom (DXCM)

Richard Newitter

Truist Financial

$82→$80

Buy

9.47%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Suraj Kalia

Oppenheimer

Hold

―

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), American Well (NYSE: AMWL) and Avita Medical (NASDAQ: RCEL)

Jeff Johnson

Robert W. Baird

$82→$87

Buy

19.05%

Upside

Reiterated

02/13/26

DexCom price target raised to $87 from $82 at BairdDexCom price target raised to $87 from $82 at Baird

Matthew Taylor

Jefferies

$112

Buy

53.26%

Upside

Reiterated

02/13/26

Dexcom (DXCM) Gets a Buy from Jefferies

Anthony Petrone

Mizuho Securities

$78→$90

Buy

23.15%

Upside

Reiterated

02/13/26

DexCom price target raised to $90 from $78 at MizuhoDexCom price target raised to $90 from $78 at Mizuho

Jonathan Block

Stifel Nicolaus

$85

Buy

16.31%

Upside

Reiterated

02/13/26

Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)

Matt Miksic

Barclays

$71→$72

Sell

-1.48%

Downside

Reiterated

02/13/26

Joanne Wuensch

Citi

Buy

―

Reiterated

02/13/26

Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Dexcom (DXCM)

Travis Steed

Bank of America Securities

$100

Buy

36.84%

Upside

Reiterated

02/13/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Josh Jennings

TD Cowen

$84

Buy

14.94%

Upside

Reiterated

02/13/26

Dexcom: Sustained Revenue Outperformance and Margin Expansion Underpin Buy Rating

Danielle Antalffy

UBS

$95

Buy

29.99%

Upside

Reiterated

02/13/26

Analysts Conflicted on These Healthcare Names: Rezolute (NASDAQ: RZLT), Dexcom (NASDAQ: DXCM) and Bruker (NASDAQ: BRKR)

William Plovanic

Canaccord Genuity

$99→$95

Buy

29.99%

Upside

Reiterated

02/13/26

DexCom price target lowered to $95 from $99 at CanaccordDexCom price target lowered to $95 from $99 at Canaccord

Larry Biegelsen

Wells Fargo

$93→$85

Buy

16.31%

Upside

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NASDAQ: NBIX), Dexcom (NASDAQ: DXCM) and Icon (NASDAQ: ICLR)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/13/26

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Marie Thibault

BTIG

$85

Buy

16.31%

Upside

Reiterated

02/18/26

BTIG Reaffirms Their Buy Rating on Dexcom (DXCM)

Richard Newitter

Truist Financial

$82→$80

Buy

9.47%

Upside

Reiterated

02/17/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX), Neurocrine (NASDAQ: NBIX) and Dexcom (NASDAQ: DXCM)

Suraj Kalia

Oppenheimer

Hold

―

Reiterated

02/13/26

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), American Well (NYSE: AMWL) and Avita Medical (NASDAQ: RCEL)

Jeff Johnson

Robert W. Baird

$82→$87

Buy

19.05%

Upside

Reiterated

02/13/26

DexCom price target raised to $87 from $82 at BairdDexCom price target raised to $87 from $82 at Baird

Matthew Taylor

Jefferies

$112

Buy

53.26%

Upside

Reiterated

02/13/26

Dexcom (DXCM) Gets a Buy from Jefferies

Anthony Petrone

Mizuho Securities

$78→$90

Buy

23.15%

Upside

Reiterated

02/13/26

DexCom price target raised to $90 from $78 at MizuhoDexCom price target raised to $90 from $78 at Mizuho

Jonathan Block

Stifel Nicolaus

$85

Buy

16.31%

Upside

Reiterated

02/13/26

Stifel Nicolaus Keeps Their Buy Rating on Dexcom (DXCM)

Matt Miksic

Barclays

$71→$72

Sell

-1.48%

Downside

Reiterated

02/13/26

Joanne Wuensch

Citi

Buy

―

Reiterated

02/13/26

Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Dexcom (DXCM)

Travis Steed

Bank of America Securities

$100

Buy

36.84%

Upside

Reiterated

02/13/26

Analysts Conflicted on These Healthcare Names: Dexcom (NASDAQ: DXCM), Vertex Pharmaceuticals (NASDAQ: VRTX) and Royalty Pharma (NASDAQ: RPRX)

Josh Jennings

TD Cowen

$84

Buy

14.94%

Upside

Reiterated

02/13/26

Dexcom: Sustained Revenue Outperformance and Margin Expansion Underpin Buy Rating

Danielle Antalffy

UBS

$95

Buy

29.99%

Upside

Reiterated

02/13/26

Analysts Conflicted on These Healthcare Names: Rezolute (NASDAQ: RZLT), Dexcom (NASDAQ: DXCM) and Bruker (NASDAQ: BRKR)

William Plovanic

Canaccord Genuity

$99→$95

Buy

29.99%

Upside

Reiterated

02/13/26

DexCom price target lowered to $95 from $99 at CanaccordDexCom price target lowered to $95 from $99 at Canaccord

Larry Biegelsen

Wells Fargo

$93→$85

Buy

16.31%

Upside

Reiterated

02/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NASDAQ: NBIX), Dexcom (NASDAQ: DXCM) and Icon (NASDAQ: ICLR)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/13/26

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

3 Months

xxx

Success Rate

27/40 ratings generated profit

Average Return

+10.38%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.50% of your transactions generating a profit, with an average return of +10.38% per trade.

1 Year

Jeff JohnsonRobert W. Baird

Success Rate

23/40 ratings generated profit

Average Return

+10.75%

reiterated a buy rating 10 days ago

Copying Jeff Johnson's trades and holding each position for 1 Year would result in 57.50% of your transactions generating a profit, with an average return of +10.75% per trade.

2 Years

xxx

Success Rate

20/33 ratings generated profit

Average Return

+27.18%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.61% of your transactions generating a profit, with an average return of +27.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DXCM has received 58 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. DXCM average Analyst price target in the past 3 months is 85.82.

Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $0.47 with a range of $0.39 to $0.53. The previous quarter’s EPS was $0.68. DXCM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $1.18B with a range of $1.16B to $1.18B. The previous quarter’s sales results were $1.26B. DXCM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year DXCM has Performed in-line its overall industry.

DXCM Stock Forecast FAQ

What is DXCM’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 85.82.

What is DXCM’s upside potential, based on the analysts’ average price target?

Dexcom has 17.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DXCM a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 1 sell ratings.

What is Dexcom’s price target?

The average price target for Dexcom is 85.82. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $112.00 ,the lowest forecast is $68.00. The average price target represents 17.43% Increase from the current price of $73.08.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of DXCM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Dexcom (DXCM) Stock Forecast & Price Target

DXCM Analyst Ratings

DXCM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DXCM Analyst Recommendation Trends

DXCM Financial Forecast

DXCM Earnings Forecast

DXCM Sales Forecast

DXCM Stock Forecast FAQ

Detailed List of Analyst Forecasts